Patent intelligence · US
US 12326492
Systems and methods of detecting interstitial cystitis
Systems and methods of detecting interstitial cystitis
Patent details — US 12326492
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 10, 2025
- Expiration
- Jun 5, 2045
- Applicant
- LIPELLA PHARMACEUTICALS, INC.
- Claims
- 40
- CPC classes
- A61K, A61K49/0004, A61K49/103, A61K49/105
Quick answer
US 12326492 (Systems and methods of detecting interstitial cystitis) is held by LIPELLA PHARMACEUTICALS, INC.. Status: granted. Granted Jun 10, 2025. Expires Jun 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LIPELLA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 40
- CPC classes
- A61K, A61K49/0004, A61K49/103, A61K49/105, A61K49/1827
More from LIPELLA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12326492?
US 12326492 (Systems and methods of detecting interstitial cystitis) is held by LIPELLA PHARMACEUTICALS, INC.. Status: granted. Granted Jun 10, 2025. Expires Jun 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12326492?
LIPELLA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12326492 expire?
Our index shows an expiration date of Jun 5, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.